莫西沙星治疗高龄社区获得性肺炎临床研究  

Clinical study of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia

作　　者：段艳红[1] 杜春玲[1] 

机构地区：[1]复旦大学附属中山医院青浦分院呼吸内科,上海201700

出　　处：《临床肺科杂志》2016年第5期841-844,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨莫西沙星治疗高龄社区获得性肺炎临床疗效及安全性。方法研究对象选取我院收治高龄社区获得性肺炎患者共64例,以随机区组法分为对照组(32例)和治疗组(32例),分别采用左氧氟沙星和莫西沙星序贯治疗;比较两组患者临床疗效,临床症状体征消失时间、病原菌清除率、治疗前后免疫功能指标水平及不良反应发生率等。结果治疗组患者临床疗效、临床症状体征消失时间及病原菌清除率均显著优于对照组(P<0.05);治疗组患者治疗后免疫功能指标均显著优于对照组、治疗前(P<0.05);治疗组患者不良反应发生率显著低于对照组(P<0.05)。结论莫西沙星治疗高龄社区获得性肺炎患者可有效改善临床疗效,缩短临床病程,提高机体免疫功能,并有助于降低不良反应发生风险。Objective To investigate the clinical effects and safety of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia. Methods 64 patients with elderly patients with community-acqnired pneumonia were chosen in the period from October 2012 to October 2014 in our hospital and randomly divided into both group including control group （32 patients） with levofloxacin and treatment group （32 patients） with moxifloxa- cin by sequential regimen including intravenous drip and orally; and the clinical efficacy, the disappeared time of clinical symptoms and signs, pathogenic bacteria clearance rate, the levels of immune function index before and after treatment and adverse reactions incidence of both groups were compared. Results The clinical efficacy, disappeared time of clinical symptoms and signs and pathogenic bacteria clearance rate of treatment group were significantly better than control group（P 〈 0. 05 ）. The levels of immune function index of treatment group after operation was significant- ly better than control group（P 〈 0. 05 ）. The adverse reactions incidence of treatment group was significantly lower than control group（P 〈 0. 05 ）. Conclusion Moxifloxacin in treatment of elderly patients with community-acquired pneumonia can efficiently improve the clinical effect, shorten the clinical course, improve the immune function and be helpful to reduce the risk of adverse reactions.

关 键 词：莫西沙星 社区获得性肺炎 疗效 免疫功能 

分 类 号：R563.1[医药卫生—呼吸系统]